Although a molecule increased by walnuts has been linked to reduced cancer cell activity in lab tests, this study did not measure cancer in people and cannot support claims that walnuts prevent cancer.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis of prospective cohort studies would determine whether walnut consumption is associated with reduced cancer incidence or mortality in humans.
A systematic review and meta-analysis of all prospective cohort studies (minimum 10) tracking walnut intake (≥30 g/day) and cancer incidence/mortality over 10+ years in adults aged 50+, adjusting for smoking, BMI, and other dietary factors.
An RCT would determine whether walnut supplementation reduces cancer incidence over time, but such a trial would require massive sample sizes and long durations.
A double-blind RCT with 10,000 adults aged 60–75, randomized to 50 g/day walnuts or placebo, followed for 15 years with annual cancer screening and adjudicated cancer diagnosis as the primary endpoint.
A cohort study could determine whether higher walnut intake predicts lower cancer incidence over time in a large population.
A prospective cohort of 15,000 adults aged 55–75 with baseline walnut intake assessed via food frequency questionnaire and cancer incidence tracked via national registries over 20 years, adjusting for confounders.
A case-control study could compare walnut intake in individuals with and without specific cancers to identify potential associations.
A case-control study comparing walnut intake over the prior 5 years in 1,000 individuals with colorectal cancer to 1,000 matched controls without cancer, using validated dietary recall and biomarker verification.
A cross-sectional study could show whether walnut consumers have lower cancer prevalence at a single point in time.
A cross-sectional survey of 5,000 adults aged 65–79 assessing current walnut intake and self-reported cancer history, adjusting for age, sex, and screening behavior.